EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Light‐Triggered PROTAC Nanoassemblies for Photodynamic IDO Proteolysis in Cancer Immunotherapy

Jiwoong Choi, Byeongmin Park, Jung Yeon Park, Dongwon Shin, Sangmin Lee, Hong Yeol Yoon, Kwangmeyung Kim, Sun Hwa Kim, Yongju Kim, Yoosoo Yang, Man Kyu Shim iD

Advanced Materials · 2024-09 · 36 (38)

DOI: 10.1002/adma.202405475 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 29.06.2024. Verfasst von Jiwoong Choi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Medicinal Materials Research Center, Biomedical Research Division, Korea Institute of Science and Technology (KIST), Seoul, 02792, Republic of Korea. Hauptthemen laut MEDLINE: Proteolysis, Indoleamine-Pyrrole 2,3,-Dioxygenase, Immunotherapy, Photochemotherapy. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Research Foundation (NRF) of Korea, Ministry of Science, Intramural Research Program of KIST.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

While proteolysis‐targeting chimeras (PROTACs) hold great potential for persistently reprogramming the immunosuppressive tumor microenvironment via targeted protein degradation, precisely activating them in tumor tissues and preventing uncontrolled proteolysis at off‐target sites remain challenging. Herein, a light‐triggered PROTAC nanoassembly (LPN) for photodynamic indoleamine 2,3‐dioxygenase (IDO) proteolysis is reported. The LPN is derived from the self‐assembly of prodrug conjugates, which comprise a PROTAC, cathepsin B‐specific cleavable peptide linker, and photosensitizer, without any additional carrier materials. In colon tumor models, intravenously injected LPNs initially silence the activity of PROTACs and accumulate significantly in targeted tumor tissues due to an enhanced permeability and retention effect. Subsequently, the cancer biomarker cathepsin B begins to trigger the release of active PROTACs from the LPNs through enzymatic cleavage of the linkers. Upon light irradiation, tumor cells undergo immunogenic cell death induced by photodynamic therapy to promote the activation of effector T cells, while the continuous IDO degradation of PROTAC simultaneously blocks tryptophan metabolite‐regulated regulatory‐T‐cell‐mediated immunosuppression. Such LPN‐mediated combinatorial photodynamic IDO proteolysis effectively inhibits tumor growth, metastasis, and recurrence. Collectively, this study presents a promising nanomedicine, designed to synergize PROTACs with other immunotherapeutic modalities, for more effective and safer cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProteolysisIndoleamine-Pyrrole 2,3,-DioxygenaseImmunotherapyPhotochemotherapyPhotosensitizing AgentsLightAnimalsMiceCell Line, TumorHumansColonic NeoplasmsNanoparticlesProdrugsTumor Microenvironment

Stichwörter der Autor:innen

cancer immunotherapyindoleamine 2,3‐dioxygenase (IDO)nanomedicinephotodynamic therapy (PDT)proteolysis‐targeting chimeras (PROTACs)

Substanzen

Indoleamine-Pyrrole 2,3,-DioxygenasePhotosensitizing AgentsProdrugs

Autor:innen und Institutionen

  • Medicinal Materials Research Center, Biomedical Research Division, Korea Institute of Science and Technology (KIST), Seoul, 02792, Republic of Korea.
  • KU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul, 02841, Republic of Korea.
  • College of Pharmacy, Graduate School of Pharmaceutical Sciences, Kyung Hee University, Seoul, 02453, Republic of Korea.
  • College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, 03760, Republic of Korea.
  • Chemical and Biological Integrative Research Center, Korea Institute of Science and Technology, Seoul, 02792, Republic of Korea.
  • Division of Bio-Medical Science and Technology, KIST School, Korea University of Science and Technology, Seoul, 02792, Republic of Korea.

ORCID-Profile: Man Kyu Shim

Förderung

  • National Research Foundation (NRF) of Korea
  • Ministry of Science
  • Intramural Research Program of KIST
  • Samsung Research Funding & Incubation Center for Future Technology of Samsung Electronics
  • Korea Institute of Science and Technology

Zitieren

APA

Choi, J., Park, B., Park, J. Y., Shin, D., Lee, S., Yoon, H. Y., Kim, K., Kim, S. H., Kim, Y., Yang, Y., & Shim, M. K. (2024). Light‐Triggered PROTAC Nanoassemblies for Photodynamic IDO Proteolysis in Cancer Immunotherapy. Advanced Materials, 36(38). https://doi.org/10.1002/adma.202405475

Vancouver

Choi J, Park B, Park JY, Shin D, Lee S, Yoon HY, et al. Light‐Triggered PROTAC Nanoassemblies for Photodynamic IDO Proteolysis in Cancer Immunotherapy. Advanced Materials. 2024;36(38). doi:10.1002/adma.202405475

BibTeX
@article{Choi2024,
  author = {Choi, Jiwoong and Park, Byeongmin and Park, Jung Yeon and Shin, Dongwon and Lee, Sangmin and Yoon, Hong Yeol and Kim, Kwangmeyung and Kim, Sun Hwa and Kim, Yongju and Yang, Yoosoo and Shim, Man Kyu},
  title = {Light‐Triggered PROTAC Nanoassemblies for Photodynamic IDO Proteolysis in Cancer Immunotherapy},
  journal = {Advanced Materials},
  year = {2024},
  volume = {36},
  number = {38},
  doi = {10.1002/adma.202405475}
}
Kostenlos starten →